In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1127-1135

  Macone, A B ^a   Caruso, B K ^a   Leahy, R G ^a   Donatelli, J ^a   Weir, S ^b   Draper, M P ^a   Tanaka, S K ^a   Levy, S B ^a  

^a Transcept Pharmaceuticals Inc   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DAPTOMYCIN; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; OMADACYCLINE; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; IN VIVO STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; TETK GENE; TETM GENE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; ESCHERICHIA COLI; GENE EXPRESSION; HAEMOPHILUS INFLUENZAE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; PERITONEUM; RIBOSOMES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TETRACYCLINES;

EID: 84893487652     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01242-13     Document Type: Article

References (43)

1. Levy SB, McMurry LM, Barbosa TM, Burdett V, Courvalin P, Hillen W, Roberts MC, Rood JI, Taylor DE. 1999. Nomenclature for new tetracycline resistance determinants. Antimicrob. Agents Chemother. 43:1523-1524.
2. Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:232-260. http://dx.doi.org/10.1128/MMBR.65.2.232- 260.2001.
3. Cai Y, Wang R, Liang B, Bai N, Liu Y. 2011. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob. Agents Chemother. 55:1162-1172. http://dx.doi.org/10.1128/AAC.01402-10.
4. Chopra I. 2001. Glycylcyclines: third-generation tetracycline antibiotics. Curr.Opin.Pharmacol.1:464-469.http://dx.doi.org/10.1016/S1471- 4892(01)00081-9.
5. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-tbutylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
6. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob. Agents Chemother. 57:5548-5558. http://dx.doi.org/10.1128/AAC.01288-13.
7. Nelson ML, Ismail MY. 2007. The Antibiotic and Nonantibiotic Tetracyclines, p 597-617. In Taylor JB, Triggle DJ (ed), Comprehensive medicinal chemistry II, vol 2. Therapeutic areas II: cancer infectious diseases, inflammation and immunology and dermatology. Elsevier, Oxford, United Kingdom
8. Bhatia B, Bowser T, Chen J, Ismail M, McIntyre L, Mechiche R, Nelson M, Ohemeng K, Verma A, Jones G, Fallon M. 2003. PTK 0796 and other novel tetracycline derivatives exhibiting potent in vitro and in vivo activities against antibiotic resistant gram-positive bacteria, abstr 2420, poster F-755. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
9. Biedenbach DJ, Mendes RE, Sader HS, Jones RN. 2010. In vitro evaluation of PTK796 activity tested against Staphylococcus aureus, including hospital-and community-associated MRSA strains from the U. S. A. and Europe, abstr E-1569. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Dubois J, Tanaka SK. 2006. In vitro activity of MK-2764/PTK 0796 against Legionella spp., abstr 1846, poster F1-1974. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
11. Macone A, Donatelli J, Dumont T, Levy SB, Tanaka SK. 2003. In vitro activity of PTK 0796 against gram-positive and gram-negative organisms, abstr 2439, poster F-754. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
12. Macone AB, Arbeit RD, Hait HI, Draper MP, Tanaka SK. 2010. Identification and susceptibility of pathogens isolated from patients with complicated skin and skin structure infections (cSSSI): results of a PTK796 (PTK) phase 2 clinical trial, abstr 3178, poster L1-1760. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
13. Sader HS, Mendes RE, Biedenbach DJ, Jones RN. 2010. Antimicrobial activity of PTK796 tested against gram-positive organisms causing bloodstream infections in 2009, abstr E-1588. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
14. Smith K, Tanaka SK, Appelbaum PC. 2006. Antistaphylococcal activity of MK-2764/PTK 0796 compared to other agents, abstr 1860, poster F1-1971. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. Traczewski MM, Brown SD. 2003. PTK 0796: In vitro potency and spectrum of activity compared to ten other antimicrobial compounds, abstr 2458, poster F-753. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
16. Weir S, Macone A, Donatelli J, Trieber C, Taylor DE, Tanaka SK, Levy SB. 2003. The mechanism of action of PTK 0796, abstr 2473, poster F-751. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
17. Weir S, Macone A, Donatelli J, Trieber C, Taylor DE, Tanaka SK, Levy SB. 2003. The activity of PTK 0796 against tetracycline resistance, abstr 2611, poster F-752. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
18. Clinical and Laboratory Standards Institute. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M07-A05. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Flamm RK, Farrell DJ, Sader HS, Jones RN. 2012. Antimicrobial activity of PTK 0796 (omadacycline) and comparator agents against contemporary pathogens commonly associated with community acquired respiratory tract infections collected during 2011 from the European Union, abstr P01449, p 383-384. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
20. Sader HS, Flamm RK, Jones RN. 2012. Antimicrobial activity of PTK 0796 (Omadacycline) tested against gram-positive organisms isolated from European Hospitals in 2011, abstr P1450, p 384. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
21. Craig WA, Andes D, Odinecs A. 2006. In vivo pharmacodynamics of MK-2764/PTK 0796 against various gram-positive and gram-negative bacteria in the thighs of neutropenic and normal mice, abstr 1875, poster F1-1974. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
22. Leahy RG, Hanley B, Macone AB, Draper MP, Tanaka SK. 2011. Comparative efficacy of omadacycline (PTK796) in lethal Streptococcus pneumoniae and Staphylococcus aureus pneumoniae models, abstr 3059, p 1074. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis., Milan, Italy, 7 to 10 May 2011.
23. Tessier PR, Fan HW, Tanaka SK, Nicolau DP. 2006. Pharmacokinetic/ pharmacodynamic profile of MK-2764/PTK 0796 against S. pneumoniae in a murine pneumonia model, abstr 1888, poster F1-1973. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
24. Yu D, Kelley KA, Osborn MN, Trzasko A, Pettiford S, McKenney D, Bradford PA. 2010. Efficacy of PTK796 in a rat MRSA infective endocarditis (IE) model, abstr B-069. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
25. Arbeit RD, Roberts JA, Forsythe AR, Johnston SM, Seyedi F, Pukshansky M, Tanaka SK. 2008. Safety and efficacy of PTK 0796: Results of the phase 2 study in complicated skin and skin structure infections following IV and oral step down therapy, abstr L-1515b. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
26. Noel GJ, Draper M, Hait H, Tanaka SK. 2012. Safety and efficacy of PTK 0796 (Omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI), abstr P694, p 123-124. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
27. Sun H, Ting L, Maietta R, Machineni S, Praestgaard J, Kuemmell A, Stein DS, Sunkara G, Kovacs SJ, Draper MP. 2012. A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects, abstr P1423, p 374-375. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
28. Ting L, Sun H, Kovacs SJ, Klausner K, Tanaka SK. 2010. Pharmacokinetics of intravenous and oral PTK796, a new aminomethylcycline antibiotic, abstr K-124. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
29. Ng LK, Martin I, Alfa M, Mulvey M. 2001. Multiplex PCR for the detection of tetracycline resistant genes. Mol. Cell. Probes 15:209-215. http://dx.doi.org/10.1006/mcpr.2001.0363.
30. Frimodt-Moller N, Knudsen JD, Espersen F. 1999. Chapter 14: The mouse peritonitis/sepsis model, p 127-136. In Zak O, Sande MA (ed), Handbook of animal models of infection. Academic Press, London, United Kingdom.
31. Cannon EP, White NM, Chaturvedi P, Esposito C, Koroma J, Tanaka SK. 2003. Phamacokinetics of PTK 0796 in mouse, rat and cynomolgus monkey, abstr 2655, poster F-759. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
32. Hait H, Arbeit R, Molnar D, Noel GJ, Tanaka SK. 2011. In a phase 2 complicated skin and soft tissue infections (cSSTI) trial outcomes assessed early in the course of therapy were consistent with outcomes assessed 10-17 days after completing therapy for patients treated with either omadacycline (OMC; PTK796) or linezolid, abstr P1528. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis., Milan, Italy, 7 to 10 May 2011.
33. Peterson LR. 2005. Antimicrobial activity and pharmacokinetics/ pharmacodynamics of the novel glycylcycline, tigecycline. Diagn. Microbiol. Infect. Dis. 52:163-164. http://dx.doi.org/10.1016/j.diagmicrobio.2005.06.011.
34. Peterson LR. 2008. A review of tigecycline-the first glycylcycline. Int. J. Antimicrob. Agents 32(Suppl 4):S215-S222. http://dx.doi.org/10.1016/S0924- 8579(09)70005-6.
35. Bradford PA, Weaver-Sands DT, Petersen PJ. 2005. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl 5):S315-S332. http://dx.doi.org/10.1086/431673.
36. Chaturvedi P, Esposito C, Koroma J, Cannon EP, Tanaka SK. 2003. In vitro assessment of plasma protein binding and metabolic stability of PTK 0796, abstr 2675, poster F-760. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
37. Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD. 2012. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 56:5650-5654. http://dx.doi.org/10. 1128/AAC.00948-12.
38. Appelbaum PC. 2002. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin. Infect. Dis. 34:1613-1620. http://dx.doi.org/10.1086/340400.
39. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
40. Devasahayam G, Scheld WM, Hoffman PS. 2010. Newer antibacterial drugs for a new century. Expert Opin. Investig. Drugs 19:215-234. http://dx.doi.org/10. 1517/13543780903505092.
41. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011. http://dx.doi.org/10.1086/591861.
42. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States.JAMA298:1763-1771. http://dx.doi.org/10. 1001/jama.298.15.1763.
43. Palmer KL, Kos VN, Gilmore MS. 2010. Horizontal gene transfer and the genomics of enterococcal antibiotic resistance. Curr. Opin. Microbiol. 13:632-639. http://dx.doi.org/10.1016/j.mib.2010.08.004.